查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1544845

非鴉片類鎮痛藥市場 - 全球行業規模、佔有率、趨勢、機會和預測，按產品細分、治療應用、配銷通路、按地區和競爭，2019-2029F

Non-Opioids Analgesics Drugs Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Products, Therapeutic Applications, Distribution Channel, By Region & Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球非鴉片類止痛藥市場價值為 7.2348 億美元，預計在預測期內將出現令人印象深刻的成長，複合年成長率為 4.08%，到 2029 年將達到 9.4508 億美元。

市場概況
預測期 2025-2029
2023 年市場規模 7.2348億美元
2029 年市場規模 91508萬美元
2024-2029 年複合年成長率 4.08%
成長最快的細分市場 骨科和肌肉骨骼疼痛
最大的市場 北美洲

在幾個關鍵促進因素的推動下，製藥業的疼痛管理領域正在經歷顯著的成長和轉型。鴉片類藥物危機引發了非鴉片類藥物替代品的根本轉變，激發了對創新止痛解決方案的需求。這項轉變凸顯了對新型藥物配方和標靶治療的迫切需求，從而重塑了疼痛管理的格局。在這個不斷發展的格局中，生物製劑和大麻素正在成為治療疼痛的有前途的途徑，為患者和醫療保健提供者提供新的選擇。此外，利用基因組學和生物標記的個人化醫療的採用正在獲得越來越多的關注，從而能夠更有效地滿足個人需求的客製化治療。

市場對針灸和瑜伽等替代療法的興趣激增，反映出整體疼痛管理方法的更廣泛趨勢。同時，先進的給藥系統和人工智慧 (AI) 的整合等技術進步正在透過提高止痛藥的功效和可及性來徹底改變止痛藥。

然而，在這些機會的同時，該產業也面臨巨大的挑戰。確保新興疼痛治療的有效性和安全性仍然至關重要，同時滿足嚴格的監管要求並解決成本和取得障礙。儘管有這些障礙，市場前景仍然樂觀，人們將共同努力開發副作用減少和成癮潛力的強效止痛藥。在治療模式的轉變、技術創新以及對個人化護理的日益重視的推動下，製藥業的疼痛管理市場正在經歷一場深刻的演變。隨著利害關係人不斷創新和合作，未來可望開發出更安全、更有效的疼痛管理解決方案，進而改善全球患者的生活。

主要市場促進因素

非鴉片類藥物開發的進展

日益關注疼痛管理替代方案

慢性疼痛加劇

主要市場挑戰

療效和患者滿意度

成本和可及性

主要市場趨勢

疼痛管理中的生物製劑

大麻素

創新藥物輸送系統

細分市場洞察

產品洞察

治療應用見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球非鴉片類鎮痛藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（醫用大麻、含薄荷醇、Omega 3 脂肪酸、肉毒桿菌、辣椒素衍生性商品）
    • 依治療應用（骨科和肌肉骨骼疼痛、神經性疼痛、癌症疼痛、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按公司分類 (2023)
    • 按地區
  • 市場地圖
    • 按產品分類
    • 按治療應用
    • 按配銷通路
    • 按地區

第 6 章：北美非鴉片類止痛藥市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按治療應用
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲非鴉片類鎮痛藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按治療應用
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區非鴉片類止痛藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按治療應用
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲非鴉片類止痛藥市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按治療應用
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲非鴉片類止痛藥市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按治療應用
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 埃及
    • 土耳其

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 14 章：臨床試驗分析

第15章：競爭格局

  • Vertex Pharmaceuticals Inc.
  • Cadence Pharmaceuticals Inc.
  • Pacira Biosciences Inc.
  • Eli Lilly and Company
  • Centrexion Therapeutics Corp.
  • Biogen Inc.
  • Novartis AG
  • GSK PLC
  • Pfizer Inc.
  • Teikoku Seiyaku Co. Ltd.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 23991

Global Non-Opioids Analgesics Drugs Market was valued at USD 723.48 million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.08% through 2029 to reach USD 945.08 Million.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 723.48 Million
Market Size 2029USD 915.08 Million
CAGR 2024-20294.08%
Fastest Growing SegmentOrthopedic and Musculoskeletal Pain
Largest MarketNorth America

The pharmaceutical industry's pain management sector is experiencing notable growth and transformation, spurred by several key drivers. The opioid crisis has triggered a fundamental shift towards non-opioid alternatives, sparking demand for innovative pain relief solutions. This shift underscores a critical need for novel drug formulations and targeted therapies, reshaping the landscape of pain management. In this evolving landscape, biologics and cannabinoids are emerging as promising avenues for pain treatment, offering fresh options for patients and healthcare providers alike. Moreover, the adoption of personalized medicine, leveraging genomics and biomarkers, is gaining traction, enabling tailored treatments that address individual needs more effectively.

The market is witnessing a surge in interest in alternative therapies like acupuncture and yoga, reflecting a broader trend towards holistic approaches to pain management. Simultaneously, technological advancements, such as advanced drug delivery systems and the integration of artificial intelligence (AI), are revolutionizing pain medication by enhancing their efficacy and accessibility.

However, amidst these opportunities, the sector faces significant challenges. Ensuring the efficacy and safety of emerging pain treatments remains paramount, alongside navigating stringent regulatory requirements and addressing cost and access barriers. Despite these obstacles, the market outlook remains optimistic, with a concerted effort towards developing potent painkillers with reduced side effects and addictive potential. The pharmaceutical industry's pain management market is undergoing a profound evolution, driven by shifts in treatment paradigms, technological innovations, and a growing emphasis on personalized care. As stakeholders continue to innovate and collaborate, the future holds promise for the development of safer, more effective pain management solutions that improve the lives of patients worldwide.

Key Market Drivers

Advancements in Non-Opioid Drug Development

The global non-opioid analgesics drugs market is experiencing robust growth, driven primarily by recent advancements in drug development. As healthcare systems around the world grapple with the challenges posed by opioid addiction and its associated risks, the focus has increasingly shifted towards non-opioid alternatives. This shift is not merely a reaction to the opioid crisis but is also indicative of a broader trend in pharmaceutical innovation aimed at delivering safer and more effective pain management solutions. New drug delivery technologies are allowing for more precise targeting of pain pathways, reducing side effects and improving efficacy. These systems include advanced formulations such as nanocarriers and liposomes that enhance the bioavailability of active ingredients while minimizing systemic exposure.

The introduction of biologics, such as monoclonal antibodies and recombinant proteins, has provided novel mechanisms of action for pain relief. These biologics, targeting specific pain pathways or inflammatory processes, offer new avenues for treatment. Biosimilars, which are highly similar to already approved biologics, further expand treatment options at potentially lower costs. Technological advancements have also led to the development of neuromodulation therapies, including transcranial magnetic stimulation (TMS) and spinal cord stimulation. These therapies are designed to alter nerve activity and provide pain relief, presenting a non-pharmacological alternative to traditional analgesics. Advances in genomics and personalized medicine are enabling the development of non-opioid analgesics tailored to individual genetic profiles. This approach aims to optimize treatment efficacy and minimize adverse effects, thus enhancing patient outcomes.

Increasing Focus on Pain Management Alternatives

In recent years, the global non-opioid analgesics drugs market has witnessed substantial growth, largely driven by an intensified focus on exploring and implementing pain management alternatives. This shift is reshaping the pharmaceutical landscape as stakeholders across the healthcare industry seek to mitigate the risks associated with opioid use while addressing the persistent need for effective pain relief. Increasing awareness of the dangers associated with opioid use has prompted regulatory bodies to impose stricter controls on opioid prescriptions. In response, healthcare providers and patients are seeking alternatives that offer effective pain relief without the risk of dependency.

The pharmaceutical industry is investing significantly in research and development to discover and refine non-opioid analgesics drugs. Advances in drug formulation, novel mechanisms of action, and emerging technologies are creating a diverse array of non-opioid options tailored to various pain conditions. There is a growing emphasis on personalized medicine, which considers individual patient profiles and specific pain management needs. This approach is fostering the development of non-opioid analgesics drugs that are tailored to enhance efficacy and minimize adverse effects, aligning with the broader trend towards individualized care. Many healthcare systems are revising their pain management protocols to incorporate non-opioid alternatives. This shift is driven by both regulatory changes and a proactive approach to combating opioid-related issues, creating a fertile environment for non-opioid analgesics drugs to thrive.

Rising Chronic Pain Conditions

The global non-opioid analgesics drugs market is experiencing significant expansion, with rising chronic pain conditions emerging as a primary driver of this growth. As the prevalence of chronic pain continues to climb, there is an increasing demand for effective and safer pain management solutions. This trend is reshaping the landscape of pain relief, highlighting the critical role of non-opioid analgesics in addressing the needs of millions of patients worldwide. The high incidence of chronic pain conditions is driving the demand for alternative analgesic options. Patients and healthcare providers are actively seeking non-opioid therapies that offer effective pain relief without the risk of addiction or adverse side effects associated with opioids.

The opioid crisis has heightened awareness of the risks associated with opioid use, including addiction and overdose. As a result, there is a concerted effort to reduce opioid prescriptions and explore non-opioid alternatives. Regulatory bodies are also promoting the development and adoption of non-opioid analgesics as part of broader strategies to combat opioid dependency. Significant progress in the development of non-opioid analgesics drugs is providing new treatment options for chronic pain sufferers. Innovations in drug formulation, targeted delivery systems, and novel drug classes are enhancing the efficacy and safety profiles of non-opioid therapies, making them more appealing to both patients and healthcare providers.

Increased awareness among patients regarding the risks of opioid use is driving demand for non-opioid alternatives. Patients are becoming more informed about their treatment options and are actively seeking safer pain management solutions that align with their long-term health goals.Healthcare systems are adapting to the rising prevalence of chronic pain by integrating non-opioid analgesics into their pain management protocols. This shift is supported by efforts to optimize pain management strategies and reduce reliance on opioids, contributing to the expansion of the non-opioid analgesics drugs market.

Key Market Challenges

Efficacy and Patient Satisfaction

One of the primary concerns with non-opioid analgesics drugs is ensuring their efficacy in managing pain, particularly in comparison to opioids. Pain is a subjective experience that varies greatly among individuals. Non-opioid analgesics drugs may not always provide sufficient relief for all patients, especially those with severe or chronic pain conditions. This variability can limit the effectiveness of these therapies and affect their overall acceptance. Many non-opioid analgesics drugs are designed to address acute pain rather than chronic pain. Chronic pain often requires long-term management strategies that go beyond the capabilities of some non-opioid drugs. This limitation can impact the perceived efficacy of these alternatives for patients with persistent pain.

Non-opioid analgesics drugs often need to demonstrate comparable or superior effectiveness to opioids to gain broader acceptance. Despite advancements in drug development, achieving this level of efficacy across a range of pain conditions remains a significant challenge. Chronic pain is a complex condition involving multiple physiological and psychological factors. Non-opioid analgesics drugs targeting specific pain pathways may not address all aspects of chronic pain, potentially leading to incomplete relief and reduced effectiveness.

Cost and Accessibility

One of the primary barriers to the widespread adoption of non-opioid analgesics drugs is their cost. The development of new non-opioid analgesics drugs involves extensive research and clinical trials, which are both time-consuming and costly. The high costs associated with bringing new drugs to market are often reflected in their retail prices, making them less affordable for patients. Many new non-opioid analgesics drugs are initially launched as branded drugs, which can command higher prices due to the costs of innovation and marketing. These premiums can limit access for patients, particularly those without adequate insurance coverage or financial resources.

While some non-opioid analgesics drugs eventually become available in generic form, many newer drugs are still under patent protection. This lack of competition can keep prices high and limit options for cost-conscious patients. Not all non-opioid analgesics drugs are covered by insurance plans, or they may be covered only at higher co-pay levels. Patients who lack comprehensive insurance or have high deductibles may find these drugs prohibitively expensive, leading to reduced access. Availability of non-opioid analgesics drugs can vary by region. In some areas, particularly in low- and middle-income countries, there may be limited access to these medications due to supply chain issues, regulatory hurdles, or lack of local production facilities. In some healthcare systems, non-opioid analgesics drugs may not be prioritized or integrated into standard treatment protocols. This can result in limited availability or underutilization of these therapies, particularly in resource-limited settings.

Key Market Trends

Biologics in Pain Management

The global non-opioid analgesics drugs market is undergoing a significant transformation, driven by the rising prominence of biologics in pain management. Biologics, which are complex molecules derived from living organisms, are emerging as a groundbreaking trend in the quest for effective, safer alternatives to traditional opioids. This shift reflects a broader movement towards more targeted and personalized approaches to pain relief, addressing a critical need in the face of the opioid crisis and the growing demand for innovative therapies.

Unlike traditional analgesics, which often act broadly and can lead to unwanted side effects, biologics are designed to target specific molecular pathways involved in pain and inflammation. This targeted approach enhances therapeutic efficacy and minimizes systemic side effects, offering a more precise method of pain management. The biologics landscape in pain management includes various types of therapies, such as monoclonal antibodies, cytokine inhibitors, and growth factors. These biologics are designed to interfere with specific pain-related processes, such as the modulation of inflammatory cytokines or the inhibition of nerve growth factors, providing new avenues for pain relief.

Biologics are at the forefront of personalized medicine, where treatments are tailored to individual patient profiles. By targeting specific biomarkers or genetic factors, biologics can offer more effective and individualized pain management solutions, improving outcomes and patient satisfaction.

Cannabinoids

As the global non-opioid analgesics drugs market continues to evolve, cannabinoids are emerging as a significant trend in pain management. Derived from the cannabis plant, cannabinoids have gained increasing attention for their potential to offer effective, alternative pain relief without the addictive risks associated with opioids. This growing interest reflects a broader shift towards more diverse and innovative approaches in managing pain and addressing the opioid crisis.

Cannabinoids interact with the endocannabinoid system, which plays a role in regulating pain, inflammation, and mood. Research suggests that cannabinoids can modulate pain perception and reduce inflammation, offering potential benefits for various pain conditions, including chronic pain, neuropathic pain, and cancer-related pain. Recent regulatory shifts, including the legalization of medical cannabis in many regions and the approval of cannabinoid-based medications by regulatory agencies, have facilitated the development and use of cannabinoids for pain management. These changes have helped legitimize cannabinoids as a viable treatment option and expanded their availability.

Increasing patient interest in alternative and natural therapies has driven the demand for cannabinoid-based treatments. Patients are seeking non-opioid options that offer effective pain relief with fewer risks and side effects compared to traditional opioids. Growing research into the efficacy and safety of cannabinoids for pain management is advancing our understanding of their potential benefits. Innovative formulations and delivery methods, such as tinctures, capsules, and topical products, are making cannabinoids more accessible and user-friendly.

Innovative Drug Delivery Systems

Innovative Drug Delivery Systems are set to profoundly influence the growth of the non-opioid analgesic drugs market in the coming years. These advancements in drug delivery technology, such as patches, implants, microneedles, and nanoparticles, offer significant benefits in improving the effectiveness and convenience of pain medications. For instance, transdermal patches can provide a steady release of medication over time, offering prolonged pain relief without the need for frequent dosing. Such systems not only enhance patient compliance but also reduce the risk of side effects associated with fluctuations in drug levels. Additionally, targeted drug delivery systems allow for more precise administration of medications to specific sites of pain, maximizing efficacy while minimizing systemic exposure. As the demand for safer and more efficient pain management solutions grows, pharmaceutical companies are increasingly investing in these innovative delivery systems. The market for non-opioid analgesics drugs is expected to expand with the development and adoption of these advanced technologies. However, challenges such as regulatory approvals, manufacturing complexities, and cost-effectiveness will need to be addressed.

Segmental Insights

Product Insights

Medical Cannabis has emerged as a dominant force in the Non-Opioid Analgesic Drugs market in 2023 for several reasons. The increasing acceptance and legalization of medical marijuana in various regions have led to a surge in its use for pain management. Cannabis contains cannabinoids, such as THC and CBD, which interact with the body's endocannabinoid system to modulate pain perception. Patients seeking alternatives to opioids for chronic pain conditions are turning to medical cannabis due to its perceived effectiveness and relatively lower risk of addiction and side effects. Moreover, the versatility of cannabis products, including oils, tinctures, edibles, and topical creams, provides patients with a range of options to choose from based on their preferences and needs. Additionally, ongoing research and clinical studies are uncovering the potential benefits of medical cannabis in alleviating neuropathic pain, arthritis, and other conditions, further bolstering its popularity and market dominance in the non-opioid analgesic drugs sector.

Therapeutic Applications Insights

The dominance of Orthopedic & Musculoskeletal pain by therapeutic applications in the Non-Opioids Analgesic Drugs market in 2023 can be attributed to several key factors. Orthopaedic, and musculoskeletal conditions such as arthritis, back pain, and injuries are prevalent globally, affecting a significant portion of the population. These conditions often result in chronic pain that requires long-term management, creating a substantial demand for effective pain relief options. Non-opioid analgesics, including NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) and topical formulations, are commonly prescribed for orthopedic and musculoskeletal pain due to their ability to reduce inflammation and alleviate discomfort. Also, the rising aging population, particularly in developed countries, is driving the prevalence of these conditions and thereby increasing the market share of non-opioid analgesics drugs tailored for orthopedic and musculoskeletal pain. Advancements in drug formulations and delivery methods, specifically designed for these types of pain, have further solidified their dominance in the market. Patients and healthcare providers alike are increasingly opting for non-opioid options due to concerns about the addictive potential and side effects of opioids.

Regional Insights

North America's dominated in the Non-Opioids Analgesic Drugs market in 2023 can be attributed to several factors. The region has been at the forefront of addressing the opioid crisis, with increased awareness and efforts to reduce opioid prescriptions and promote non-opioid alternatives. This has led to a significant shift in prescribing patterns towards non-opioid analgesics drugs or pain management. Also, the region boasts a well-established healthcare infrastructure and regulatory framework that supports the development and adoption of non-opioid medications. North America also has a higher prevalence of chronic pain conditions, such as arthritis and lower back pain, which drives the demand for effective pain relief options. The region's aging population is another contributing factor, as older individuals are more likely to experience chronic pain and seek non-opioid treatments. Pharmaceutical companies in North America are actively investing in research and development of innovative non-opioid analgesics drugs, capitalizing on the growing market demand. The availability of a wide range of non-opioid options, including topical formulations, NSAIDs, and medical cannabis, further cements North America's dominance in the Non-Opioids Analgesic Drugs market.

Key Market Players

Vertex Pharmaceuticals Inc.

Cadence Pharmaceuticals Inc.

Pacira Biosciences Inc.

Eli Lilly and Company

Centrexion Therapeutics Corp.

Biogen Inc.

Novartis AG

GSK PLC

Pfizer Inc.

Teikoku Seiyaku Co. Ltd.

Report Scope:

In this report, the Global Non-Opioids Analgesics Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Opioids Analgesics Drugs Market, By Products:

    Medical Cannabis Menthol- Containing Omega 3 Fatty Acid Botulinum Toxins Capsaicin Derived

Non-Opioids Analgesics Drugs Market, By Therapeutic Applications:

    Orthopedic and Musculoskeletal Pain Neuropathic Pain Cancer Pain Others

Non-Opioids Analgesics Drugs Market, By Distribution Channel:

    Hospital Pharmacies Retail Pharmacies Online Pharmacies

Non-Opioids Analgesics Drugs Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Opioids Analgesics Drugs Market.

Available Customizations:

Global Non-Opioids Analgesics Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Non-Opioids Analgesics Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Products (Medical Cannabis, Menthol- Containing, Omega 3 Fatty Acid, Botulinum Toxins, Capsaicin Derived)
    • 5.2.2. By Therapeutic Applications (Orthopaedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Company (2023)
    • 5.2.5. By Region
  • 5.3. Market Map
    • 5.3.1. By Products
    • 5.3.2. By Therapeutic Applications
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Non-Opioids Analgesics Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Products
    • 6.2.2. By Therapeutic Applications
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Opioids Analgesics Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Products
        • 6.3.1.2.2. By Therapeutic Applications
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Mexico Non-Opioids Analgesics Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Products
        • 6.3.2.2.2. By Therapeutic Applications
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Canada Non-Opioids Analgesics Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Products
        • 6.3.3.2.2. By Therapeutic Applications
        • 6.3.3.2.3. By Distribution Channel

7. Europe Non-Opioids Analgesics Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Products
    • 7.2.2. By Therapeutic Applications
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Products
        • 7.3.1.2.2. By Therapeutic Applications
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Products
        • 7.3.2.2.2. By Therapeutic Applications
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Products
        • 7.3.3.2.2. By Therapeutic Applications
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Products
        • 7.3.4.2.2. By Therapeutic Applications
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Products
        • 7.3.5.2.2. By Therapeutic Applications
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Non-Opioids Analgesics Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Products
    • 8.2.2. By Therapeutic Applications
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Products
        • 8.3.1.2.2. By Therapeutic Applications
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Products
        • 8.3.2.2.2. By Therapeutic Applications
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. South Korea Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Products
        • 8.3.3.2.2. By Therapeutic Applications
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. Japan Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Products
        • 8.3.4.2.2. By Therapeutic Applications
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Products
        • 8.3.5.2.2. By Therapeutic Applications
        • 8.3.5.2.3. By Distribution Channel

9. South America Non-Opioids Analgesics Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Products
    • 9.2.2. By Therapeutic Applications
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Non-Opioids Analgesics Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Products
        • 9.3.1.2.2. By Therapeutic Applications
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Non-Opioids Analgesics Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Products
        • 9.3.2.2.2. By Therapeutic Applications
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Non-Opioids Analgesics Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Products
        • 9.3.3.2.2. By Therapeutic Applications
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Non-Opioids Analgesics Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Products
    • 10.2.2. By Therapeutic Applications
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Non-Opioids Analgesics Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Products
        • 10.3.1.2.2. By Therapeutic Applications
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Non-Opioids Analgesics Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Products
        • 10.3.2.2.2. By Therapeutic Applications
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Non-Opioids Analgesics Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Products
        • 10.3.3.2.2. By Therapeutic Applications
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. Egypt Non-Opioids Analgesics Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Products
        • 10.3.4.2.2. By Therapeutic Applications
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Turkey Non-Opioids Analgesics Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Products
        • 10.3.5.2.2. By Therapeutic Applications
        • 10.3.5.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Clinical Trial Analysis

  • 14.1. Ongoing Clinical Trials
  • 14.2. Completed Clinical Trials
  • 14.3. Terminated Clinical Trials
  • 14.4. Breakdown of Pipeline, By Development Phase
  • 14.5. Breakdown of Pipeline, By Status
  • 14.6. Breakdown of Pipeline, By Therapeutic Area
  • 14.7. Breakdown of Pipeline, By Region
  • 14.8. Clinical Trials Heat Map

15. Competitive Landscape

  • 15.1. Vertex Pharmaceuticals Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Cadence Pharmaceuticals Inc.
  • 15.3. Pacira Biosciences Inc.
  • 15.4. Eli Lilly and Company
  • 15.5. Centrexion Therapeutics Corp.
  • 15.6. Biogen Inc.
  • 15.7. Novartis AG
  • 15.8. GSK PLC
  • 15.9. Pfizer Inc.
  • 15.10. Teikoku Seiyaku Co. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer